Most cases of insulin-dependent diabetes are discovered only when symptoms appear. But through a sophisticated screening program offered at the University of Florida, individuals and family members can find out whether the chronic disorder is all but certain to develop in the future.
Type 1 Diabetes TrialNet is an NIH-sponsored clinical trials network of researchers dedicated to the study, prevention, and early treatment of type 1 diabetes. Currently, there are 18 Clinical Centers in the US, including at the University of Florida, and over 200 affiliate sites. Since inception, Type 1 Diabetes TrialNet has screened over 200,000 people for disease risk. TrialNet at UF has screened over 13,000 family members.
The purpose of TrialNet is to:
- Conduct studies designed to evaluate new approaches to prevent or ameliorate type 1 diabetes; and
- Further define epidemiology, natural history, risk factors, and mechanisms leading to type 1 diabetes.
University of Florida TrialNet researchers seek to identify family members at risk, and evaluate promising new therapies to prevent, slow or reverse the progression of the disease. The Pathway to Prevention study offers a blood test that can identify the risk for type 1 diabetes up to 10 years before symptoms actually appear. TrialNet at UF researches have screened nearly 3,500 participants in this study, with the hopes of reducing complications and helping countless others at risk for type 1 diabetes.